

Matej Skorvanek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/238011/publications.pdf>

Version: 2024-02-01

66
papers

1,632
citations

304743

22
h-index

345221

36
g-index

66
all docs

66
docs citations

66
times ranked

2465
citing authors

#	ARTICLE	IF	CITATIONS
1	Blood DNA methylation provides an accurate biomarker of <i>KMT2B</i>-related dystonia and predicts onset. <i>Brain</i> , 2022, 145, 644-654.	7.6	18
2	WARS2 mutations cause dopa-responsive early-onset parkinsonism and progressive myoclonus ataxia. <i>Parkinsonism and Related Disorders</i> , 2022, 94, 54-61.	2.2	13
3	Effect of Pillbox Organizers with Alarms on Adherence to Pharmacotherapy in Parkinson Disease Patients Taking Three and More Daily Doses of Dopaminergic Medications. <i>Journal of Personalized Medicine</i> , 2022, 12, 179.	2.5	2
4	Prevalence of Fabry Disease among Patients with Parkinson's Disease. <i>Parkinson's Disease</i> , 2022, 2022, 1-8.	1.1	3
5	Impact of the COVID-19 outbreak on neurological consultation in an emergency department. <i>Acta Neurologica Belgica</i> , 2022, , 1.	1.1	0
6	Does the 5â€²-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5â€²-1-positive patients in 7 countries. <i>BMC Neurology</i> , 2022, 22, 35.	1.8	12
7	Alzheimer's Disease-Associated SNP rs708727 in SLC41A1 May Increase Risk for Parkinson's Disease: Report from Enlarged Slovak Study. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1604.	4.1	4
8	Validation of the Arabic Version of the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Movement Disorders</i> , 2022, 37, 826-841.	3.9	2
9	Skin Conditions and Movement Disorders: Hiding in Plain Sight. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 566-583.	1.5	3
10	Progressive choreodystonia in X-linked <sc>hyper&lgM</sc> immunodeficiency: a rare but recurrent presentation. <i>Annals of Clinical and Translational Neurology</i> , 2022, , .	3.7	0
11	Genetic overlap between dystonia and other neurologic disorders: A study of 1,100 exomes. <i>Parkinsonism and Related Disorders</i> , 2022, 102, 1-6.	2.2	8
12	Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations. <i>Movement Disorders</i> , 2021, 36, 283-297.	3.9	52
13	Atypical presentations of DYT1 dystonia with acute craniocervical onset. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 54-55.	2.2	1
14	LRRK2 mutations in Parkinson's disease patients from Central Europe: A case control study. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 110-112.	2.2	1
15	Predictors of outcome events and 6-year mortality after carotid endarterectomy and carotid stenting in patients with carotid artery stenosis. <i>Neurologia i Neurochirurgia Polska</i> , 2021, 55, 67-73.	1.2	5
16	<i>De novo</i> variants in neurodevelopmental disordersâ€™ experiences from a tertiary care center. <i>Clinical Genetics</i> , 2021, 100, 14-28.	2.0	64
17	Variant recurrence confirms the existence of a <i>FBXO31</i>-related spastic&dystonic cerebral palsy syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 951-955.	3.7	6
18	Clinically relevant copy-number variants in exome sequencing data of patients with dystonia. <i>Parkinsonism and Related Disorders</i> , 2021, 84, 129-134.	2.2	15

#	ARTICLE	IF	CITATIONS
19	A Recurrent <i>VPS16</i> p.Arg187* Nonsense Variant in Early-Onset Generalized Dystonia. <i>Movement Disorders</i> , 2021, 36, 1984-1985.	3.9	7
20	Scoring Algorithm-Based Genomic Testing in Dystonia: A Prospective Validation Study. <i>Movement Disorders</i> , 2021, 36, 1959-1964.	3.9	7
21	Comparison in detection of prodromal Parkinson's disease patients using original and updated MDS research criteria in two independent cohorts. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 48-55.	2.2	5
22	The neurological and neuropsychiatric spectrum of adults with late-treated phenylketonuria. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 167-175.	2.2	11
23	Dystonia as a prominent presenting feature in developmental and epileptic encephalopathies: A case series. <i>Parkinsonism and Related Disorders</i> , 2021, 90, 73-78.	2.2	9
24	for , , and in Parkinson™s. <i>Neuromethods</i> , 2021, , 227-269.	0.3	0
25	Whole exome sequencing identifies a homozygous <i>POLG2</i> missense variant in an adult patient presenting with optic atrophy, movement disorders, premature ovarian failure and mitochondrial DNA depletion. <i>European Journal of Medical Genetics</i> , 2020, 63, 103821.	1.3	5
26	Monogenic variants in dystonia: an exome-wide sequencing study. <i>Lancet Neurology</i> , The, 2020, 19, 908-918.	10.2	139
27	Lack of Accredited Clinical Training in Movement Disorders in Europe, Egypt, and Tunisia. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1833-1843.	2.8	3
28	Answer to Finsterer about "Multisystem presentation of a homozygous <i>POLG2</i> variant". <i>European Journal of Medical Genetics</i> , 2020, 63, 103900.	1.3	0
29	Recessive null-allele variants in <i>MAG</i> associated with spastic ataxia, nystagmus, neuropathy, and dystonia. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 70-75.	2.2	3
30	Loss-of-Function Variants in <i>HOPS</i> Complex Genes <i>VPS16</i> and <i>VPS41</i> Cause Early Onset Dystonia Associated with Lysosomal Abnormalities. <i>Annals of Neurology</i> , 2020, 88, 867-877.	5.3	70
31	Prevalence of non-motor symptoms and their association with quality of life in cervical dystonia. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 613-622.	2.1	22
32	Update on the Management of Parkinson™s Disease for General Neurologists. <i>Parkinson's Disease</i> , 2020, 2020, 1-13.	1.1	33
33	Neuromodulation Options and Patient Selection for Parkinson's Disease. <i>Neurology India</i> , 2020, 68, 170.	0.4	2
34	Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication. <i>Frontiers in Neurology</i> , 2019, 10, 799.	2.4	34
35	Neurodevelopmental disorder associated with <i>IRF2BPL</i> gene mutation: Expanding the phenotype?. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 239-241.	2.2	20
36	Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2019, 34, 791-798.	3.9	49

#	ARTICLE	IF	CITATIONS
37	Recessive variants in ZNF142 cause a complex neurodevelopmental disorder with intellectual disability, speech impairment, seizures, and dystonia. <i>Genetics in Medicine</i> , 2019, 21, 2532-2542.	2.4	17
38	Extensive validation study of the Parkinson's Disease Composite Scale. <i>European Journal of Neurology</i> , 2019, 26, 1281-1288.	3.3	8
39	Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. <i>Movement Disorders</i> , 2018, 33, 499-500.	3.9	2
40	Randomised controlled trial of escitalopram for cervical dystonia with dystonic jerks/tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 579-585.	1.9	15
41	Validation study of the hoehn and yahr scale included in the MDSâ€šUPDRS. <i>Movement Disorders</i> , 2018, 33, 651-652.	3.9	32
42	Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 83-89.	2.2	46
43	Ataxia Telangiectasia Gene Mutation in Isolated Segmental Dystonia Without Ataxia and Telangiectasia. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 89-91.	1.5	11
44	Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018, 33, 208-218.	3.9	138
45	Î±â€šSynuclein antibody 5G4 identifies manifest and prodromal Parkinson's disease in colonic mucosa. <i>Movement Disorders</i> , 2018, 33, 1366-1368.	3.9	12
46	Reply: Hoehn and Yahr stage 3 and Postural stability item in the Movement Disorder Societyâ€šUnified Parkinson's Disease Rating Scale. <i>Movement Disorders</i> , 2018, 33, 1189-1190.	3.9	0
47	Accuracy of Rating Scales and Clinical Measures for Screening of Rapid Eye Movement Sleep Behavior Disorder and for Predicting Conversion to Parkinsonâ€šs Disease and Other Synucleinopathies. <i>Frontiers in Neurology</i> , 2018, 9, 376.	2.4	39
48	Differences in <scp>MDS</scp>â€šUPDRS</scp> Scores Based on Hoehn and Yahr Stage and Disease Duration. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 536-544.	1.5	65
49	Prevalence of Prodromal Parkinsonâ€šs Disease as Defined by MDS Research Criteria among Elderly Patients Undergoing Colonoscopy. <i>Journal of Parkinson's Disease</i> , 2017, 7, 481-489.	2.8	12
50	Opsoclonus-myoclonus ataxia syndrome secondary to venlafaxine intoxication. <i>Journal of the Neurological Sciences</i> , 2017, 372, 19-20.	0.6	7
51	Measurement of Nonmotor Symptoms in Clinical Practice. <i>International Review of Neurobiology</i> , 2017, 133, 291-345.	2.0	18
52	The Skin and Parkinson's Disease: Review of Clinical, Diagnostic, and Therapeutic Issues. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 21-31.	1.5	37
53	Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin. <i>Frontiers in Neurology</i> , 2017, 8, 35.	2.4	63
54	Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. <i>European Journal of Neurology</i> , 2016, 23, 772-779.	3.3	12

#	ARTICLE	IF	CITATIONS
55	Rating Scales for Pain in Parkinson's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 527-537.	1.5	46
56	Paroxysmal exercise-induced dystonia within the phenotypic spectrum of <i>ECHS1</i> deficiency. <i>Movement Disorders</i> , 2016, 31, 1041-1048.	3.9	58
57	Validation of the Official Slovak Version of the Unified Dyskinesia Rating Scale (UDysRS). <i>Parkinson's Disease</i> , 2015, 2015, 1-7.	1.1	4
58	Relationship between the non-motor items of the MDSâ€“UPDRS and Quality of Life in patients with Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2015, 353, 87-91.	0.6	58
59	The associations between fatigue, apathy, and depression in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 80-87.	2.1	93
60	The role of social support in anxiety and depression among Parkinsonâ€™s disease patients. <i>Disability and Rehabilitation</i> , 2014, 36, 2044-2049.	1.8	24
61	The Clinical Syndrome of Paroxysmal Exercise-Induced Dystonia: Diagnostic Outcomes and an Algorithm. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 57-61.	1.5	100
62	Selfâ€“rated health mediates the association between functional status and healthâ€“related quality of life in Parkinson's disease. <i>Journal of Clinical Nursing</i> , 2014, 23, 1970-1977.	3.0	5
63	Exploding head syndrome â€“ a rare parasomnia or a dissociative episode?. <i>Sleep Medicine</i> , 2014, 15, 728-730.	1.6	10
64	Influence of Disease Severity on Fatigue in Patients with Parkinson's Disease Is Mainly Mediated by Symptoms of Depression. <i>European Neurology</i> , 2013, 70, 201-209.	1.4	13
65	Apathy in Elderly Nondemented Patients With Parkinson's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2013, 26, 237-243.	2.3	30
66	Clinical determinants of primary and secondary fatigue in patients with Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2013, 260, 1554-1561.	3.6	29